TY - JOUR
T1 - Vaccines for lung cancer
AU - Hirschowitz, Edward A.
AU - Hiestand, David M.
AU - Yannelli, John R.
PY - 2006/1
Y1 - 2006/1
N2 - Immunotherapy is based on the knowledge that the immune system can distinguish cancerous cells from normal cells. Conceptually, this is an attractive adjuvant approach because it is highly specific and can deal with disseminated disease with minimal impact on normal tissues. In this review, we focus on strategies that use host immune machinery to generate anti-tumor effects, known as active immunotherapy. Proof of principle in lung cancer is now well established in clinical trials, although no superior approach has been defined and therapeutic efficacy remains unknown. In this review, we discuss rationale, biological theory, application, and clinical implementation to date.
AB - Immunotherapy is based on the knowledge that the immune system can distinguish cancerous cells from normal cells. Conceptually, this is an attractive adjuvant approach because it is highly specific and can deal with disseminated disease with minimal impact on normal tissues. In this review, we focus on strategies that use host immune machinery to generate anti-tumor effects, known as active immunotherapy. Proof of principle in lung cancer is now well established in clinical trials, although no superior approach has been defined and therapeutic efficacy remains unknown. In this review, we discuss rationale, biological theory, application, and clinical implementation to date.
KW - Immunotherapy
KW - Lung cancer
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=34247881863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247881863&partnerID=8YFLogxK
U2 - 10.1097/01243894-200601000-00019
DO - 10.1097/01243894-200601000-00019
M3 - Review article
C2 - 17409835
AN - SCOPUS:34247881863
SN - 1556-0864
VL - 1
SP - 93
EP - 104
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 1
ER -
